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Acute respiratory infections (ARIs) are 
increasingly recognized as triggers of acute 
cardiovascular events [1]. Observational 
studies using large electronic healthcare 
databases have shown an approximately 
2–5-fold transient increase in the risk of 
acute myocardial infarction (AMI), stroke, 
and other thrombotic events such as 
deep venous thrombosis after ARI [2–4]. 
Although the definition of ARI in these 
studies is frequently based on clinical, 
rather than microbiological, criteria evi-
dence that some specific infections trigger 
vascular events comes indirectly from vac-
cine trials. One meta-analysis of random-
ized controlled trials of influenza vaccine 
in patients with existing cardiovascular 
disease showed a reduced risk of major 
adverse cardiovascular outcomes at 1 year 
[5]. For pneumococcal vaccine, meta-anal-
yses of observational studies suggest a small 
protective effect against cardiovascular 
events in people aged >65 years [6, 7], but 
controlled trial evidence is lacking. In peo-
ple who develop ARI, unanswered ques-
tions about how different ARI treatments 
might modulate vascular risk remain.
Nonsteroidal anti-inflammatory drugs 
(NSAIDs) are widely used to reduce pain, 
fever, and inflammation associated with 
acute infections as well as symptoms 
of chronic musculoskeletal and other 
inflammatory conditions. Although the 
risk of gastrointestinal hemorrhage asso-
ciated with these drugs has long been 
recognized, in recent years attention has 
focussed on adverse cardiovascular effects. 
Initially, concerns about increased risk of 
acute cardiovascular events arose when 
the new class-selective cyclooxygenase 
2 (COX-2) inhibitors, with lower risks 
of gastrointestinal bleeding, were intro-
duced [8–10]. However, a growing body 
of evidence has now established that risks 
of vascular events are increased by tra-
ditional nonselective NSAIDs, notably 
diclofenac [11]. The US Food and Drug 
Administration recommended that the 
selective COX-2 inhibitors rofecoxib and 
valdecoxib be removed from the market in 
2004 and 2005 [12] and recently issued a 
black-box warning that NSAIDs can cause 
heart attacks [13]. In the United Kingdom, 
the National Institute for Health and Care 
Excellence recommends cautious pre-
scription of NSAIDs based on assessing 
an individual’s risk factors such as history 
of cardiovascular and gastrointestinal ill-
ness, using the lowest effective dose for 
the shortest duration necessary to control 
symptoms, and opting for naproxen or 
low-dose ibuprofen for their more favor-
able thrombotic cardiovascular safety pro-
file [14]. Nevertheless, some NSAIDs such 
as ibuprofen are widely available over the 
counter, and in the United States, NSAIDS 
are reportedly taken at least once per week 
by 50% of people aged >65 years [15].
In this issue of the Journal of Infectious 
Diseases, Wen and colleagues provide 
evidence for a dual effect of acute respi-
ratory infection and NSAIDs on myo-
cardial infarction risk in a case crossover 
study of 9793 patients from Taiwan [16]. 
Using comprehensive claims data over a 
7-year period from the National Health 
Research Insurance Database, which cov-
ers approximately 99% of the population, 
they showed that acute respiratory infec-
tions treated with NSAIDs had a stron-
ger association with AMI than ARIs not 
treated with NSAIDs or NSAID treat-
ment alone. A series of sensitivity analyses 
strengthened the validity of the results and 
reduced the risk of bias due to inappropri-
ate control time-window selection. This 
study represents an important step toward 
understanding the interaction between 
transient, nontraditional AMI risk factors.
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The effects of NSAIDs are largely medi-
ated through inhibition of COX, which 
prevents the conversion of arachidonic 
acid into its biologically active deriva-
tives [17] and, thus, profoundly alters 
prostaglandin homeostasis [15]. Different 
NSAIDs have different activity profiles 
against the COX-1 and COX-2 isoforms. 
It is likely that the cardiovascular risk 
associated with nonselective and COX-2 
inhibitors results from various mecha-
nisms, including altering the balance of 
thromboxane and prostacyclin, leading to 
increased platelet aggregation and vaso-
constriction, as well as fluid and sodium 
retention [17]. Acute respiratory infec-
tions induce a range of hemodynamic, 
procoagulant, and proinflammatory 
effects that contribute to the risk of cardiac 
complications [18]. It is certainly plausible 
that interaction between these deleteri-
ous mechanisms may, in part, explain the 
greater risk of AMI seen in individuals 
with ARIs treated with NSAIDs compared 
with those with untreated ARIs or those 
with NSAID use alone.
The case-crossover design has the 
major advantage of eliminating the effect 
of fixed between-person confounders, as 
each individual serves as their own con-
trol over time [19]. Specifically, in the 
study by Wen and colleagues the effect 
of exposure to ARI and NSAIDs on AMI 
was compared within a case period and 
a control period for each patient. The 
authors also adjusted for time-varying 
confounding due to discordant concom-
itant medication use in their multivari-
able analysis. One potential limitation of 
the chosen design, however, which was 
noted by the authors in the discussion, 
is the risk of confounding by indication 
[20]. This is the situation in which the 
clinical indication for prescribing drugs 
such as NSAIDs (eg, severity of ARI, 
fever, and pain) also affects the risk of 
experiencing the outcome (here, AMI). 
Although a sensitivity analysis to inves-
tigate the effect of NSAID use during 
different types of ARI showed that 
AMI risk was higher with NSAID use 
for influenza-related ARIs compared to 
other ARIs and no ARI, the limited data 
on illness severity available in health 
insurance claims databases makes this 
impossible to evaluate further. The largest 
effect size was seen for parenteral NSAID 
use in the context of ARI, which again 
might suggest a more severe underlying 
illness. Both improving data availability 
on infection severity and considering the 
use of methods such as propensity scores 
to reduce bias [21] will be important for 
future research in this area.
An important unanswered question 
that will inform clinical practice relates to 
the differential effects of specific NSAIDs 
used for symptomatic ARI relief on car-
diovascular risk. In a supplementary anal-
ysis, Wen and colleagues stratified by type 
of NSAID to investigate separately the 
effects of diclofenac, mefenamic acid, the 
selective COX-2 inhibitors used in Taiwan 
(celecoxib, rofecoxib, and etorcoxib), and 
use of multiple nonparenteral NSAIDs 
during an ARI. No data were available 
on the effects of naproxen or ibuprofen, 
the two NSAIDs currently considered to 
have the most favorable thrombotic car-
diovascular safety profiles [14]. Although 
minor differences in effect size were seen 
among different nonparenteral NSAIDs, 
the overlapping confidence intervals 
and relatively small sample sizes in each 
stratum make these results difficult to 
interpret. Although it is mechanistically 
plausible that, in the context of ARI as in 
other settings, selective COX-2 inhibitors 
may induce greater cardiac risk than some 
nonselective agents, this is not yet evident 
from available data.
In moving from considering ARI symp-
tomatic treatments to designing targeted 
prevention strategies, it will be necessary 
to understand the relative contributions 
that different respiratory organisms make 
to vascular risk. In the study by Wen and 
colleagues, ARI episodes were based on 
codes for outpatient visits with clinically 
diagnosed infection, rather than laborato-
ry-confirmed organisms, but the authors 
note that a good correlation (0.71) has 
previously been shown between the codes 
used and the presence of respiratory patho-
gens. Other approaches that have been 
used to infer the causative organism from 
medical records data include using timing 
of an infection relative to specific organism 
circulation in the community, the influ-
enza vaccination status of the patient, and 
codes used to classify an illness [22], but 
this is not an exact science. Basing studies 
on laboratory indices of infection will help 
to inform the use of targeted vaccinations 
to reduce vascular risk. Whereas influenza 
and pneumococcal vaccines are currently 
recommended for some groups at high risk 
of cardiovascular complications, including 
those aged >65 years and people with exist-
ing heart disease [23], better understand-
ing the organisms involved will improve 
mechanistic understanding and help to 
inform clinical trials and design of preven-
tive and therapeutic interventions.
The report by Wen and colleagues con-
tributes to the evidence for dual effects of 
AMI triggers and highlights the need for 
cautious use of NSAIDs in the context 
of ARI; clinicians should consider both 
medical conditions and existing medica-
tions when prescribing NSAIDs for symp-
tomatic ARI relief. Where NSAID use 
is deemed necessary, those judged safer 
from a CVD perspective, notably ibupro-
fen or naproxen, should be used. The role 
of antiviral agents such as neuraminidase 
inhibitors was not assessed in the study 
by Wen and colleagues, but these should 
be considered as a treatment option, espe-
cially for severely ill patients admitted to 
hospital with an ARI likely due to influenza 
[13]. In the future, better characterization 
of the interactions between infections, 
NSAIDs, and other genetic, sociodemo-
graphic, and clinical cardiovascular disease 
risk factors will help to inform stratified 
ARI management. Furthermore, studies of 
interventions such as influenza and pneu-
mococcal vaccinations to reduce the risk of 
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ARIs triggering cardiac events may provide 
findings that influence routine care in the 
near future.
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